Tonny Studsgaard Petersen

Tonny Studsgaard Petersen

Auto-generated profile, based on publicly available information

Tonny Studsgaard Petersen

Department of Clinical Medicine, University of Copenhagen

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2017 in Drugs
Verified
Journal Article
Closed access
PDF file
MLMarie Lund
Marie Lund
TPTonny Studsgaard Petersen
Tonny Studsgaard Petersen
KDKim Peder Dalhoff
Kim Peder Dalhoff

23 October 2018 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
MSMichaela Louise Schiøtz
Michaela Louise Schiøtz
AFAnne Frølich
Anne Frølich
AJAnette K. Jensen
Anette K. Jensen
LRLene Reuther
Lene Reuther
HPHans Perrild
Hans Perrild
MCMikkel B. Christensen
Mikkel B. Christensen
Polypharmacy is common among multimorbid adults and associated with increased morbidity and mortality. Excessive polypharmacy (ie, ≥10 medicine) is strongly associated with inappropriate medication use, but little is known about attitudes toward deprescribing in patients with excessive polypharmacy. We surveyed 100 Danish individuals aged 65 years and above with ≥10 prescribed medications, using the validated Patients’ Attitudes Towards Deprescribing (PATD) instrument. Most participants (81, 81%) thought they took a large number of medications, and 79 (79%) believed that their medications were necessary. Even so, 85 (85%) reported that they would be willing to stop taking one or more of their regular medications if their doctor told them they could, and 11 (11%) felt that they took at least one regular medication that they no longer needed. When presented with visual presentation of various amounts of tablets and capsules, 62 (62%) of participants reported that they would be comfortable taking fewer medications than they did. Forty‐two (42%) participants had experience with stopping a regular medication. Almost all participants (92%) wanted to receive follow‐up by various means if a medication was discontinued. Forty‐one (41%) participants were interested in a consultation at an outpatient clinic specializing in polypharmacy. Overall, the answers to the PATD questionnaire suggest that our cohort of Danish, multimorbid outpatients with extensive polypharmacy have a high confidence in their healthcare providers for medication‐related decisions, even though some feel that they are taking more medications than they would like to and feel that some medications may be unnecessary. Our results underline the need for healthcare providers to offer medication reviews in patients with multimorbidity.

1 March 2015 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
TPT.S. Petersen
T.S. Petersen
SKS.G. Kristensen
S.G. Kristensen
JJJ.V. Jeppesen
J.V. Jeppesen
MGM.L. Grøndahl
M.L. Grøndahl
MWM.L. Wissing
M.L. Wissing
CAClaus Yding Andersen
Claus Yding Andersen

24 May 2018 in Clinical Toxicology
Verified
Journal Article
Closed access
LSLars E. Schmidt
Lars E. Schmidt
DRDitlev N. Rasmussen
Ditlev N. Rasmussen
TPTonny S. Petersen
Tonny S. Petersen
IMInes M. Macias-Perez
Ines M. Macias-Perez
LPLeo Pavliv
Leo Pavliv
KDKim Dalhoff
Kim Dalhoff
Context: The intravenous (IV) N-acetylcysteine (NAC) regimen used worldwide in paracetamol overdose is complex with three separate weight-based doses and is associated with a high incidence of adverse events including non-allergic anaphylactoid reactions (NAARs). In 2012, Denmark adopted the two-bag IV NAC regimen which combined the first two infusions of the three-bag regimen and kept the third infusion unchanged. We compared the safety and efficacy of the two-bag IV NAC regimen with the traditional Danish three-bag regimen. Methods: A medical chart review was conducted in three Danish medical centers from January 2012 through December 2014. Safety and efficacy data were compared for patients who received the traditional infusion protocol in Denmark or the 20-h two-bag IV regimen. Results: Four hundred and ninety-three cases received the two-bag regimen and 274 received the three-bag regimen. The overall incidence of NAARs was 9% with all being mild to moderate in intensity. Fewer subjects in the two-bag group (4%) developed NAARs compared to 17% in the three-bag group (p < .001). Overall, 31 patients (4%) developed hepatotoxicity. There was no apparent difference in hepatotoxicity rates between the groups and no deaths or liver transplants. Patients receiving the two-bag regimen had fewer interruptions or delays (5%) compared to the three-bag regimen cohort (12%). Overall, there were very few medication errors reported (1%). Conclusions: The incidence of NAARs was lower in patients receiving acetylcysteine in a two-bag regimen compared to the traditional Danish three-bag regimen without an apparent reduction in efficacy.

3 November 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KPKasper M. Petersen
Kasper M. Petersen
SBSøren Bøgevig
Søren Bøgevig
TRTroels Riis
Troels Riis
NANiklas W. Andersson
Niklas W. Andersson
KDKim P. Dalhoff
Kim P. Dalhoff
MCMikkel B. Christensen
Mikkel B. Christensen
Background: Intravenous high‐dose glucagon is a recommended antidote against beta‐blocker poisonings, but clinical effects are unclear. We therefore investigated hemodynamic effects and safety of high‐dose glucagon with and without concomitant beta‐blockade. Methods and Results: In a randomized crossover study, 10 healthy men received combinations of esmolol (1.25 mg/kg bolus+0.75 mg/kg/min infusion), glucagon (50 µg/kg), and identical volumes of saline placebo on 5 separate days in random order (saline+saline; esmolol+saline; esmolol+glucagon bolus; saline+glucagon infusion; saline+glucagon bolus). On individual days, esmolol/saline was infused from −15 to 30 minutes. Glucagon/saline was administered from 0 minutes as a 2‐minute intravenous bolus or as a 30‐minute infusion (same total glucagon dose). End points were hemodynamic and adverse effects of glucagon compared with saline. Compared with saline, glucagon bolus increased mean heart rate by 13.0 beats per minute (95% CI, 8.0–18.0; P <0.001), systolic blood pressure by 15.6 mm Hg (95% CI, 8.0–23.2; P =0.002), diastolic blood pressure by 9.4 mm Hg (95% CI, 6.3–12.6; P <0.001), and cardiac output by 18.0 % (95% CI, 9.7–26.9; P =0.003) at the 5‐minute time point on days without beta‐blockade. Similar effects of glucagon bolus occurred on days with beta‐blockade and between 15 and 30 minutes during infusion. Hemodynamic effects of glucagon thus reflected pharmacologic glucagon plasma concentrations. Glucagon‐induced nausea occurred in 80% of participants despite ondansetron pretreatment. Conclusions: High‐dose glucagon boluses had significant hemodynamic effects regardless of beta‐blockade. A glucagon infusion had comparable and apparently longer‐lasting effects compared with bolus, indicating that infusion may be preferable to bolus injections. Registration Information: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03533179.

11 October 2018 in Clinical Toxicology
Verified
Journal Article
Closed access
LHLotte Christine Groth Hoegberg
Lotte Christine Groth Hoegberg
FRFrank Refsgaard
Frank Refsgaard
SPSteen Hauge Pedersen
Steen Hauge Pedersen
MPMark Personne
Mark Personne
SUShahid Ullah
Shahid Ullah
AAAnita Annas
Anita Annas
Objective: Extended release (ER) tablets/capsules in massive ingestion overdoses are prone to form pharmacobezoars potentially increasing the risk of late-appearing toxic effects and prolonged symptoms. Oral activated charcoal is often sufficient to prevent drug absorption, but in a recent massive ingestion of highly toxic substances, prior orogastric lavage might be considered. The disintegration characteristics of ER preparations in overdose situations is valuable to understand if the time line and course of the intoxication might be prolonged, but information on these characteristics are unavailable. Slow disintegration and/or pharmacobezoar formation, and the large size makes ER preparation impossible to evacuate using a 30F orogastric lavage tube. This study evaluates the disintegration and pharmacobezoar formation of a simulated massive ER tablet ingestion in an in vitro model, using a selection of extended release tablets, with different disintegrating characteristics when present in therapeutic numbers. Furthermore, the sizes of the formed pharmacobezoars were compared with the dimensions of a 30F orogastric lavage tube. Method: A standardized model mimicking the physical effects on pharmaceutical preparations in simulated gastric fluid (SGF) was developed and tested on three mono-depot ER tablets (quetiapine/Seroquel®XR 50 mg, paracetamol/Pinex®Retard 500 mg, verapamil/Isoptin®Retard 240 mg), one poly-depot ER tablet (carbamazepine/Tegretol®Retard 200 mg), and one immediate-release tablet (paracetamol/Panodil® 500mg). Thirty tablets were placed in polyamide mesh bags, either together in one bag or in separate bags, immersed in 1 L SGF, and incubated at 37 °C for 48 h. Released drugs were quantified at 0.5–48 h. Results: Visual inspection showed that Seroquel®XR, Pinex®Retard, and Isoptin®Retard tablets formed firm pharmacobezoars stable for more than 4 h and intact fractions remained for up to 24 h. Drug releases were reduced by 53%, 40%, and 31%, respectively, for up to 8 h compared to separated tablets. Light microscopy showed that contact with SGF transformed the coating of Seroquel®XR and Pinex®Retard to a diffusion-controlled swelled gel-layer, and the Isoptin®Retard tablets into a rigid and slow-releasing matrix. Tegretol®Retard disintegrated into microspheres within 30 min, and Panodil® disintegrated within minutes. Discussion: The developed pharmacobezoars of mono-depot ER tablets demonstrated prolonged drug release. Neither the formed pharmacobezoars, nor the single tablets of the tested mono-depot ER preparations, would pass through the lumen of a standard orogastric lavage tube, rendering this modality ineffective for tablet removal in gastrointestinal decontamination.